 Glaukos Corporation NYSE: GKOS the Company or Glaukos, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today the pricing of its private offering of 250 million aggregate principal amount of 2.75 Convertible Senior Notes due 2027 the notes. The offering size was increased from the previously announced offering size of 200 million aggregate principal amount of notes. The notes were offered only to qualified institutional buyers in accordance with Rule 144A under the Securities Act of 1933, as amended the Securities Act. Glaukos has granted to the initial purchasers of the notes a 13-day option to purchase up to an additional 37.5 million aggregate principal amount of notes. The offering of the notes is expected to close on June 11, 2020, subject to customary closing conditions. 